Jianghong An
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jianghong An has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Steven J. M. Jones
Canada’s Michael Smith Genome Sciences Centre
5 shared publications - Yvonne Y. Li
Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia V5Z 4S6, Canada
3 shared publications - Angela Tam
Canada’s Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada
2 shared publications - Eric Chuah
Canada’s Michael Smith Genome Sciences Centre, British Columbia Cancer, Vancouver, BC V5Z-4S6, Canada
2 shared publications - Inanc Birol
Canada’s Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
2 shared publications - Jefferson Terry
Children’s and Women’s Health Centre of British Columbia & University of British Columbia
2 shared publications
Latest Publications
- Open Access
- 12 December 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (4) , 923-928
Identification of Compound Heterozygous CYP11A1 Variants via Reanalysis of Clinical Sequencing Data
A molecular diagnosis is currently achievable in approximately 50% of patients assessed by clinical geneticists at tertiary care centres. Next‐Generation Sequencing Panels contain a defined group of genes associated with a clinically defined set of phenotypes. Most clinical sequencing providers streamline their wet‐bench workflows by sequencing the entire exome or genome, followed by targeted bioinformatic extraction of variant data from a pre‐specified gene set. Thus, additional data on these patients remain available but are only reviewed by special request. We interrogated clinical‐grade sequencing data on two out of three affected members of a family with childhood‐onset adrenal insufficiency in whom an autosomal recessive condition was suspected. Review of clinome data identified heterozygosity for CYP11A1 variants c.644T>C; p.(Phe215Ser) and c.1187G>A; p.(Arg396Lys) in both affected sibs. Long‐read whole genome sequencing of the proband showed these variants were in trans , confirming compound heterozygosity and resolving the molecular etiology of the clinical diagnosis.
- 12 December 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (4) , 923-928
Open AccessIdentification of Compound Heterozygous CYP11A1 Variants via Reanalysis of Clinical Sequencing Data
A molecular diagnosis is currently achievable in approximately 50% of patients assessed by clinical geneticists at tertiary care centres. Next‐Generation Sequencing Panels contain a defined group of genes associated with a clinically defined set of phenotypes. Most clinical sequencing providers streamline their wet‐bench workflows by sequencing the entire exome or genome, followed by targeted bioinformatic extraction of variant data from a pre‐specified gene set. Thus, additional data on these patients remain available but are only reviewed by special request. We interrogated clinical‐grade sequencing data on two out of three affected members of a family with childhood‐onset adrenal insufficiency in whom an autosomal recessive condition was suspected. Review of clinome data identified heterozygosity for CYP11A1 variants c.644T>C; p.(Phe215Ser) and c.1187G>A; p.(Arg396Lys) in both affected sibs. Long‐read whole genome sequencing of the proband showed these variants were in trans , confirming compound heterozygosity and resolving the molecular etiology of the clinical diagnosis.
- Open Access
ACE 2 Coding Variants: A Potential X-linked Risk Factor for COVID-19 Disease
Viral genetic variants are widely known to influence disease progression among infected humans. Given the recent and rapid emergence of pandemic SARS-CoV-2 infection, the cause of COVID-19 disease, viral protein variants have attracted research interest. However, little has yet been written about genetic risk factors among human hosts. Human genetic variation has proven to affect disease progression and outcome for important diseases such as HIV infection and malaria infestation. The fact that the human ACE2 protein is encoded on the X chromosome means that males who carry rare ACE2 coding variants will express those variants in all ACE2-expressing cells, whereas females will typically express those variants in a mosaic distribution determined by early X-inactivation events. This sex-based difference in ACE2 expression has unique implications for epidemiological studies designed to assess host genetic factors influencing progression from asymptomatic SARS-coV-2 infection to COVID-19. Here we present theoretical modelling of rare ACE2 coding variants documented to occur naturally in several human superpopulations and subpopulations, and show that rare variants predicted to affect the binding of ACE2 to the SARS-CoV-2 spike protein exist in people. Though the rs4646116 (p.Lys26Arg) allele is found in 1 in 70 Ashkenazi Jewish males, and in 1 in 172 non-Finnish European males, this allele is found at higher frequencies in females. Furthermore, the class of missense ACE2 alleles predicted to affect SARS-CoV-2 binding are found in aggregate among 1.43% and 2.16% of Ashkenazi males and females, respectively, as well as in 0.58% and 1.24% of European males and females outside of Finland. These alleles are rarer in other population groups, and almost absent from East Asians genotyped to date. Though we are aware that full genome-wide and exome-wide sequencing studies may ultimately be required to assess human genetic susceptibility to SARS-CoV-2 fully, we argue on the basis of strong prior probabilities that genotyping of this class of alleles is justified in cases of atypical SARS-CoV-2 diseases, such as asymptomatic super-spreaders (if any are identified), and in neonatal/paediatric-onset COVID-19 disease. Even relatively rare susceptibility factors (1% or fewer carriers) may become quantitatively important in the context of hundreds of thousands of infections. A small number of asymptomatic carriers, or a small number of super-spreaders, or a small segment of the population that is disproportionately likely to require intensive care, can magnify the medical, social and economic impacts of a pandemic of this size. The speed of the pandemic and the large number of affected cases worldwide justify efforts to identify all possible risk factors for adverse outcomes, including efforts to identify genetic susceptibility factors in human hosts.
Open AccessACE 2 Coding Variants: A Potential X-linked Risk Factor for COVID-19 Disease
Viral genetic variants are widely known to influence disease progression among infected humans. Given the recent and rapid emergence of pandemic SARS-CoV-2 infection, the cause of COVID-19 disease, viral protein variants have attracted research interest. However, little has yet been written about genetic risk factors among human hosts. Human genetic variation has proven to affect disease progression and outcome for important diseases such as HIV infection and malaria infestation. The fact that the human ACE2 protein is encoded on the X chromosome means that males who carry rare ACE2 coding variants will express those variants in all ACE2-expressing cells, whereas females will typically express those variants in a mosaic distribution determined by early X-inactivation events. This sex-based difference in ACE2 expression has unique implications for epidemiological studies designed to assess host genetic factors influencing progression from asymptomatic SARS-coV-2 infection to COVID-19. Here we present theoretical modelling of rare ACE2 coding variants documented to occur naturally in several human superpopulations and subpopulations, and show that rare variants predicted to affect the binding of ACE2 to the SARS-CoV-2 spike protein exist in people. Though the rs4646116 (p.Lys26Arg) allele is found in 1 in 70 Ashkenazi Jewish males, and in 1 in 172 non-Finnish European males, this allele is found at higher frequencies in females. Furthermore, the class of missense ACE2 alleles predicted to affect SARS-CoV-2 binding are found in aggregate among 1.43% and 2.16% of Ashkenazi males and females, respectively, as well as in 0.58% and 1.24% of European males and females outside of Finland. These alleles are rarer in other population groups, and almost absent from East Asians genotyped to date. Though we are aware that full genome-wide and exome-wide sequencing studies may ultimately be required to assess human genetic susceptibility to SARS-CoV-2 fully, we argue on the basis of strong prior probabilities that genotyping of this class of alleles is justified in cases of atypical SARS-CoV-2 diseases, such as asymptomatic super-spreaders (if any are identified), and in neonatal/paediatric-onset COVID-19 disease. Even relatively rare susceptibility factors (1% or fewer carriers) may become quantitatively important in the context of hundreds of thousands of infections. A small number of asymptomatic carriers, or a small number of super-spreaders, or a small segment of the population that is disproportionately likely to require intensive care, can magnify the medical, social and economic impacts of a pandemic of this size. The speed of the pandemic and the large number of affected cases worldwide justify efforts to identify all possible risk factors for adverse outcomes, including efforts to identify genetic susceptibility factors in human hosts.
- Open Access
- 9 August 2010
- Published by Springer Nature in Genome Biology
- Vol. 11 (8) , R82
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
Background: Adenocarcinomas of the tongue are rare and represent the minority (20 to 25%) of salivary gland tumors affecting the tongue. We investigated the utility of massively parallel sequencing to characterize an adenocarcinoma of the tongue, before and after treatment. Results: In the pre-treatment tumor we identified 7,629 genes within regions of copy number gain. There were 1,078 genes that exhibited increased expression relative to the blood and unrelated tumors and four genes contained somatic protein-coding mutations. Our analysis suggested the tumor cells were driven by the RET oncogene. Genes whose protein products are targeted by the RET inhibitors sunitinib and sorafenib correlated with being amplified and or highly expressed. Consistent with our observations, administration of sunitinib was associated with stable disease lasting 4 months, after which the lung lesions began to grow. Administration of sorafenib and sulindac provided disease stabilization for an additional 3 months after which the cancer progressed and new lesions appeared. A recurring metastasis possessed 7,288 genes within copy number amplicons, 385 genes exhibiting increased expression relative to other tumors and 9 new somatic protein coding mutations. The observed mutations and amplifications were consistent with therapeutic resistance arising through activation of the MAPK and AKT pathways. Conclusions: We conclude that complete genomic characterization of a rare tumor has the potential to aid in clinical decision making and identifying therapeutic approaches where no established treatment protocols exist. These results also provide direct in vivo genomic evidence for mutational evolution within a tumor under drug selection and potential mechanisms of drug resistance accrual.
- 9 August 2010
- Published by Springer Nature in Genome Biology
- Vol. 11 (8) , R82
Open AccessEvolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
Background: Adenocarcinomas of the tongue are rare and represent the minority (20 to 25%) of salivary gland tumors affecting the tongue. We investigated the utility of massively parallel sequencing to characterize an adenocarcinoma of the tongue, before and after treatment. Results: In the pre-treatment tumor we identified 7,629 genes within regions of copy number gain. There were 1,078 genes that exhibited increased expression relative to the blood and unrelated tumors and four genes contained somatic protein-coding mutations. Our analysis suggested the tumor cells were driven by the RET oncogene. Genes whose protein products are targeted by the RET inhibitors sunitinib and sorafenib correlated with being amplified and or highly expressed. Consistent with our observations, administration of sunitinib was associated with stable disease lasting 4 months, after which the lung lesions began to grow. Administration of sorafenib and sulindac provided disease stabilization for an additional 3 months after which the cancer progressed and new lesions appeared. A recurring metastasis possessed 7,288 genes within copy number amplicons, 385 genes exhibiting increased expression relative to other tumors and 9 new somatic protein coding mutations. The observed mutations and amplifications were consistent with therapeutic resistance arising through activation of the MAPK and AKT pathways. Conclusions: We conclude that complete genomic characterization of a rare tumor has the potential to aid in clinical decision making and identifying therapeutic approaches where no established treatment protocols exist. These results also provide direct in vivo genomic evidence for mutational evolution within a tumor under drug selection and potential mechanisms of drug resistance accrual.
- Open Access
- 1 January 2010
- Published by Springer Nature in Genome Biology
- Vol. 11 (Suppl 1) , I5
Personalized oncogenomics
- 1 January 2010
- Published by Springer Nature in Genome Biology
- Vol. 11 (Suppl 1) , I5
Open AccessPersonalized oncogenomics
- 1 January 2006
- Vol. 17 (2) , 239-47
A large-scale computational approach to drug repositioning.
We have developed a computational pipeline for the prediction of protein-small molecule interactions and have applied it to the drug repositioning problem through a large-scale analysis of known drug targets and small molecule drugs. Our pipeline combines forward and inverse docking, the latter of which is a twist on the conventional docking procedure used in drug discovery: instead of docking many compounds against a specific target to look for potential inhibitors, one compound is docked against many proteins to search for potential targets. We collected an extensive set of 1,055 approved small molecule drugs and 1,548 drug target binding pockets (representing 78 unique human protein therapeutic targets) and performed a large-scale docking using ICM software to both validate our method and predict novel protein-drug interactions. For the 37 known protein-drug interactions in our data set that have a known structure complex, all docked conformations were within 2.0A of the solved conformation, and 30 of these had a docking score passing the typical ICM score threshold. Out of the 237 known protein-drug interactions annotated by DrugBank, 74 passed the score threshold, and 52 showed the drug docking to another protein with a better docking score than to its known target. These protein targets are implicated in human diseases, so novel protein-drug interactions discovered represent potential novel indications for the drugs. Our results highlight the promising nature of the inverse docking method for identifying potential novel therapeutic uses for existing drugs.
- 1 January 2006
- Vol. 17 (2) , 239-47
A large-scale computational approach to drug repositioning.
We have developed a computational pipeline for the prediction of protein-small molecule interactions and have applied it to the drug repositioning problem through a large-scale analysis of known drug targets and small molecule drugs. Our pipeline combines forward and inverse docking, the latter of which is a twist on the conventional docking procedure used in drug discovery: instead of docking many compounds against a specific target to look for potential inhibitors, one compound is docked against many proteins to search for potential targets. We collected an extensive set of 1,055 approved small molecule drugs and 1,548 drug target binding pockets (representing 78 unique human protein therapeutic targets) and performed a large-scale docking using ICM software to both validate our method and predict novel protein-drug interactions. For the 37 known protein-drug interactions in our data set that have a known structure complex, all docked conformations were within 2.0A of the solved conformation, and 30 of these had a docking score passing the typical ICM score threshold. Out of the 237 known protein-drug interactions annotated by DrugBank, 74 passed the score threshold, and 52 showed the drug docking to another protein with a better docking score than to its known target. These protein targets are implicated in human diseases, so novel protein-drug interactions discovered represent potential novel indications for the drugs. Our results highlight the promising nature of the inverse docking method for identifying potential novel therapeutic uses for existing drugs.